Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease
Objective: To investigate patients with Parkinson’s disease (PD) who received zonisamide and istradefylline at the same period. Background: Zonisamide and istradefylline are anti-PD drugs with…Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson’s Disease
Objective: Investigate the potential of tozadenant (TOZ) to alleviate the non-motor symptoms of Parkinson's disease using multiple animal models. Background: TOZ is an oral, selective…Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease
Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis
Objective: The aim of this meta-analysis was to provide strong evidence for the main and side effects of istradefylline on patients with Parkinson’s disease. Background:…Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.
Objective: This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)
Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease
Objective: The aim of this meta-analysis is to synthesize evidence about the efficacy of the adenosine receptor antagonists (Istradefylline and Preladenant) for patients with Parkinson’s…Anxiolytic-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) in rodent models of anxiety
Objective: The aim of this study was to assess the anxiolytic effects of istradefylline (KW-6002), an adenosine A2A receptor antagonist, in naive and anxiety-prone animals…Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease
Objective: Istradefylline is a selective antagonist of adenosine A2A receptor and was approved first in Japan for Parkinson's disease (PD) patients with by symptoms of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.